Home › Companies › Edgewise Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Edgewise Therapeutics, Inc.’s Form 8-K, filed 2026-06-05 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Proxy season: 2024-2025 2025-2026
Explore Edgewise Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Edgewise Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-05 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Laura Brege | 87,300,827 | -- | -- | 3,822,867 | -- | Majority: yes |
| Elect Director: Badreddin Edris, Ph.D. | 64,082,681 | -- | -- | 27,041,013 | -- | Majority: yes |
| Elect Director: Jonathan Root, M.D. | 59,213,781 | -- | -- | 31,909,913 | -- | Majority: yes |
| Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm | 99,637,228 | 1,123 | 578,031 | -- | -- | Majority: yes |
| Proposal 3: Advisory Vote on the Compensation of the Company's Named Executive Officers | 87,055,111 | 3,491,326 | 577,257 | -- | -- | Majority: yes |
Source: Edgewise Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-05 — read the filing on EDGAR.
Each item below shows how the 247 asset managers that disclosed a Edgewise Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Edgewise Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Edgewise Therapeutics, Inc.’s own tally for this item (“Proposal 3: Advisory Vote on the Compensation of the Company's Named Executive Officers”): 87,055,111 for, 3,491,326 against, per its Form 8-K filed 2026-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 107,481,522 outstanding shares: 81% for, 3% against (84% of the company cast a for/against vote).
The 245 asset managers below cast 95% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 15,518,492 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 10,399,068 | 0 | 0 | 0 | For |
| Janus Henderson | 7,384,469 | 0 | 0 | 0 | For |
| Paradigm Biocapital Advisors LP | 6,256,954 | 0 | 0 | 0 | For |
| BlackRock | 5,900,205 | 17,483 | 0 | 0 | For |
| Novo Holdings A/S | 5,350,000 | 0 | 0 | 0 | For |
| Vanguard | 4,909,127 | 5 | 1 | 0 | For |
| Siren, L.L.C. | 4,330,263 | 0 | 0 | 0 | For |
| Fidelity | 1,540,433 | 2,123,242 | 0 | 0 | Against |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2,877,926 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 2,432,969 | 0 | 0 | 0 | For |
| AllianceBernstein | 2,066,996 | 0 | 0 | 0 | For |
| Cormorant Asset Management, LP | 1,922,264 | 0 | 0 | 0 | For |
| American Century | 0 | 1,855,947 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 1,761,673 | 0 | 0 | 0 | For |
| Victory Capital | 1,760,035 | 0 | 0 | 0 | For |
| State Street | 1,522,847 | 2,314 | 0 | 0 | For |
| Soleus Capital Management, L.P. | 1,429,915 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,423,997 | 0 | 0 | 0 | For |
| Charles Schwab | 1,201,385 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 1,157,401 | 0 | 0 | 0 | For |
| First Light Asset Management, LLC | 878,654 | 0 | 0 | 0 | For |
| Aberdeen | 826,059 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 658,224 | 0 | 0 | 0 | For |
| BRAIDWELL LP | 651,820 | 0 | 0 | 0 | For |
Showing the 25 largest of 245 asset managers. See all 245 in the interactive database.
Combines 6 wordings of this item as funds reported it.
70% Majority: yes · of votes cast
Edgewise Therapeutics, Inc.’s own tally for this item (“Elect Director: Badreddin Edris, Ph.D.”): 64,082,681 for, 27,041,013 withheld, per its Form 8-K filed 2026-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 107,481,522 outstanding shares: 60% for, 25% withheld (85% of the company cast a for/withheld vote).
The 72 asset managers below cast 100% of the shares they voted on this item FOR (9,011,914 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,302,779 | 0 | 41 | 0 | For |
| BlackRock | 0 | 0 | 3,540,101 | 0 | Abstain |
| Fidelity | 1,516,739 | 0 | 1,081,850 | 0 | For |
| JANUS INVESTMENT FUND | 659,237 | 0 | 764,760 | 0 | Abstain |
| Victory Capital | 0 | 0 | 903,702 | 0 | Abstain |
| American Century | 0 | 0 | 881,302 | 0 | Abstain |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 658,224 | 0 | Abstain |
| Charles Schwab | 596,640 | 0 | 0 | 0 | For |
| AllianceBernstein | 518,283 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 370,215 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 297,886 | 0 | Abstain |
| Equitable | 192,828 | 0 | 95,732 | 0 | For |
| TIAA | 0 | 0 | 259,211 | 0 | Abstain |
| State Street | 190,046 | 0 | 144 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 0 | 0 | 151,637 | 0 | Abstain |
| Prudential/PGIM | 0 | 0 | 136,422 | 0 | Abstain |
| AIG/SunAmerica | 0 | 0 | 130,325 | 0 | Abstain |
| Principal | 125,329 | 0 | 4,555 | 0 | For |
| Jackson National | 0 | 0 | 127,263 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 109,592 | 0 | Abstain |
| Lincoln Financial | 52,134 | 0 | 39,310 | 0 | For |
| RBB FUND, INC. | 0 | 0 | 90,077 | 0 | Abstain |
| Allspring | 0 | 0 | 87,556 | 0 | Abstain |
| ALPS ETF Trust | 0 | 0 | 87,326 | 0 | Abstain |
| Neuberger Berman | 77,373 | 0 | 0 | 0 | For |
Showing the 25 largest of 72 asset managers. See all 72 in the interactive database.
Combines 6 wordings of this item as funds reported it.
65% Majority: yes · of votes cast
Edgewise Therapeutics, Inc.’s own tally for this item (“Elect Director: Jonathan Root, M.D.”): 59,213,781 for, 31,909,913 withheld, per its Form 8-K filed 2026-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 107,481,522 outstanding shares: 55% for, 30% withheld (85% of the company cast a for/withheld vote).
The 72 asset managers below cast 100% of the shares they voted on this item FOR (8,037,314 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,299,650 | 0 | 3,170 | 0 | For |
| BlackRock | 0 | 0 | 3,540,101 | 0 | Abstain |
| Fidelity | 1,516,739 | 0 | 1,081,850 | 0 | For |
| JANUS INVESTMENT FUND | 1,423,997 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 903,702 | 0 | Abstain |
| American Century | 0 | 0 | 881,302 | 0 | Abstain |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 658,224 | 0 | Abstain |
| Charles Schwab | 0 | 0 | 596,640 | 0 | Abstain |
| AllianceBernstein | 0 | 0 | 518,283 | 0 | Abstain |
| AB DISCOVERY GROWTH FUND, INC. | 0 | 0 | 370,215 | 0 | Abstain |
| Dimensional | 0 | 0 | 297,886 | 0 | Abstain |
| Equitable | 0 | 0 | 288,560 | 0 | Abstain |
| TIAA | 259,211 | 0 | 0 | 0 | For |
| State Street | 258 | 0 | 189,932 | 0 | Abstain |
| TRUST FOR PROFESSIONAL MANAGERS | 0 | 0 | 151,637 | 0 | Abstain |
| Prudential/PGIM | 0 | 0 | 136,422 | 0 | Abstain |
| AIG/SunAmerica | 0 | 0 | 130,325 | 0 | Abstain |
| Principal | 0 | 0 | 129,884 | 0 | Abstain |
| Jackson National | 0 | 0 | 127,263 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 109,592 | 0 | Abstain |
| Lincoln Financial | 6,134 | 0 | 85,310 | 0 | Abstain |
| RBB FUND, INC. | 0 | 0 | 90,077 | 0 | Abstain |
| Allspring | 0 | 0 | 87,556 | 0 | Abstain |
| ALPS ETF Trust | 0 | 0 | 87,326 | 0 | Abstain |
| Neuberger Berman | 77,373 | 0 | 0 | 0 | For |
Showing the 25 largest of 72 asset managers. See all 72 in the interactive database.
Combines 6 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Edgewise Therapeutics, Inc.’s own tally for this item (“Elect Director: Laura Brege”): 87,300,827 for, 3,822,867 withheld, per its Form 8-K filed 2026-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 107,481,522 outstanding shares: 81% for, 4% withheld (85% of the company cast a for/withheld vote).
The 72 asset managers below cast 100% of the shares they voted on this item FOR (17,565,125 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,299,693 | 0 | 3,127 | 0 | For |
| BlackRock | 3,540,101 | 0 | 0 | 0 | For |
| Fidelity | 1,540,433 | 0 | 1,058,156 | 0 | For |
| JANUS INVESTMENT FUND | 1,423,997 | 0 | 0 | 0 | For |
| Victory Capital | 903,702 | 0 | 0 | 0 | For |
| American Century | 881,302 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 658,224 | 0 | 0 | 0 | For |
| Charles Schwab | 596,640 | 0 | 0 | 0 | For |
| AllianceBernstein | 518,283 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 370,215 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 297,886 | 0 | Abstain |
| Equitable | 288,560 | 0 | 0 | 0 | For |
| TIAA | 259,211 | 0 | 0 | 0 | For |
| State Street | 190,190 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 151,637 | 0 | 0 | 0 | For |
| Prudential/PGIM | 132,040 | 0 | 4,382 | 0 | For |
| AIG/SunAmerica | 130,325 | 0 | 0 | 0 | For |
| Principal | 129,884 | 0 | 0 | 0 | For |
| Jackson National | 113,413 | 0 | 13,850 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 109,592 | 0 | 0 | 0 | For |
| Lincoln Financial | 91,444 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 90,077 | 0 | 0 | 0 | For |
| Allspring | 87,556 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 87,326 | 0 | 0 | 0 | For |
| Neuberger Berman | 77,373 | 0 | 0 | 0 | For |
Showing the 25 largest of 72 asset managers. See all 72 in the interactive database.
99.9% Majority: yes · of votes cast
Edgewise Therapeutics, Inc.’s own tally for this item (“Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm”): 99,637,228 for, 1,123 against, per its Form 8-K filed 2026-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 107,481,522 outstanding shares: 93% for, 0.1% against (93% of the company cast a for/against vote).
The 70 asset managers below cast 100% of the shares they voted on this item FOR (18,965,101 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,302,819 | 0 | 1 | 0 | For |
| BlackRock | 3,540,101 | 0 | 0 | 0 | For |
| Fidelity | 2,598,589 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,423,997 | 0 | 0 | 0 | For |
| Victory Capital | 903,702 | 0 | 0 | 0 | For |
| American Century | 881,302 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 658,224 | 0 | 0 | 0 | For |
| Charles Schwab | 596,640 | 0 | 0 | 0 | For |
| AllianceBernstein | 518,283 | 0 | 0 | 0 | For |
| AB DISCOVERY GROWTH FUND, INC. | 370,215 | 0 | 0 | 0 | For |
| Dimensional | 297,886 | 0 | 0 | 0 | For |
| Equitable | 288,560 | 0 | 0 | 0 | For |
| TIAA | 259,211 | 0 | 0 | 0 | For |
| State Street | 190,190 | 0 | 0 | 0 | For |
| TRUST FOR PROFESSIONAL MANAGERS | 151,637 | 0 | 0 | 0 | For |
| Prudential/PGIM | 136,422 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 130,325 | 0 | 0 | 0 | For |
| Principal | 129,884 | 0 | 0 | 0 | For |
| Jackson National | 127,263 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 109,592 | 0 | 0 | 0 | For |
| Lincoln Financial | 91,444 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 90,077 | 0 | 0 | 0 | For |
| Allspring | 87,556 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 87,326 | 0 | 0 | 0 | For |
| Neuberger Berman | 77,373 | 0 | 0 | 0 | For |
Showing the 25 largest of 70 asset managers. See all 70 in the interactive database.
Combines 2 wordings of this item as funds reported it.
100% fund support · no official result
The 2 asset managers below cast 100% of the shares they voted on this item FOR (21,331 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Eleva Capital SAS | 17,460 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 3,871 | 0 | 0 | 0 | For |
Ranked by the number of Edgewise Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 107,481,522 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ORBIMED ADVISORS LLC | 14.44% |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 9.68% |
| 3 | Janus Henderson | 6.87% |
| 4 | Paradigm Biocapital Advisors LP | 5.82% |
| 5 | BlackRock | 5.51% |
| 6 | Novo Holdings A/S | 4.98% |
| 7 | Vanguard | 4.57% |
| 8 | Siren, L.L.C. | 4.03% |
| 9 | Fidelity | 3.41% |
| 10 | DRIEHAUS CAPITAL MANAGEMENT LLC | 2.68% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Paradigm BioCapital Advisors LP | 9.50% | 13G |
| BlackRock | 6.02% | 13F |
| JANUS HENDERSON GROUP PLC | 5.50% | 13G |
| Novo Holdings A/S | 4.98% | 13D |
| Vanguard Group | 4.53% | 13F |
| Morgan Stanley | 2.71% | 13F |
| Geode Capital | 1.67% | 13F |
| State Street | 1.60% | 13F |
| Dimensional Fund Advisors | 1.13% | 13F |
| FMR (Fidelity) | 0.95% | 13F |
Percentages above are of 107,481,522 shares outstanding, as reported by Edgewise Therapeutics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Edgewise Therapeutics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Edgewise Therapeutics, Inc.'s shareholder meeting held 2026-06-04, in the 2025-2026 proxy season, 247 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,357 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — CONDUCT AN ADVISORY VOTE ON THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — FOR was 96% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Edgewise Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-05.
Edgewise Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).